Cholangiocarcinoma Market, By Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy, and Others), By Distrib

Cholangiocarcinoma Market, By Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Bile duct cancer is also called as cholangiocarcinoma. Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct. The bile duct carries a fluid called bile, which is secreted in the liver and stored in the gall bladder. The essential function of bile is to breakdown the fats during digestion. Signs of bile duct cancer include jaundice and pain in the abdomen. There are two types of bile duct cancer intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic bile duct cancer occurs in the parts of the bile ducts within the liver. Extrahepatic bile duct cancer is a rare cancer that forms in the bile ducts outside the liver.
Market Dynamics
Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as collaborations, which are expected to drive the market growth during the forecast period. For instance, In March 2021, QED Therapeutics collaborated with Helsinn Group, is a privately-owned Swiss Pharma Company. The collaboration intends to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer). Moreover, In February 2019, Imbrium Therapeutics L.P., in collaboration with Mundipharma EDO GmbH, a part of the Mundipharma-network, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.
Key features of the study:
This report provides an in-depth analysis of the global cholangiocarcinoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cholangiocarcinoma market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market
Detailed Segmentation:
Global Cholangiocarcinoma Market, By Treatment Type:
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Capecitabine
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
Global Cholangiocarcinoma Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Cholangiocarcinoma Market, By Region:
North America
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Capecitabine
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Capecitabine
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Capecitabine
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Capecitabine
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Capecitabine
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Capecitabine
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Incyte Corporation*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Eisai Co., Ltd.
QED Therapeutics, Inc.
Agios Pharmaceuticals, Inc.
RenovoRx
Ability Pharmaceuticals
Imbrium Therapeutics L.P.
Delcath Systems, Inc.
“*” marked represents similar segmentation in other categories in the respective section.